Monexe (Valsartan, Hydrochlorothiazide)

Valsartan blocks angiotensin II type 1 receptors, preventing vasoconstriction and aldosterone‑mediated sodium retention. Hydrochlorothiazide inhibits sodium‑chloride reabsorption in the distal convoluted tubule, increasing urine output and reducing plasma volume. Together they produce a synergistic reduction in blood pressure.

The specific dose of Monexe is determined by the prescribing clinician based on the patient’s blood pressure, renal function, and response to therapy. Dosage adjustments are individualized, and patients should follow the prescriber’s written instructions.

Safety of Monexe in pregnancy has not been established, and it is generally contraindicated because valsartan may cause fetal toxicity. Breastfeeding is not recommended without medical advice, as the drug can be excreted in milk and affect the infant.

To order Monexe, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Monexe combines an ARB (valsartan) with a thiazide diuretic, offering a dual mechanism that can be more effective than either component alone. Compared with single‑agent therapy such as losartan or hydrochlorothiazide alone, the combination often achieves better blood‑pressure control with a single tablet, simplifying regimens.

Monexe tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original container, protect from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Monexe is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a full glass of water. Patients should not crush or chew the tablet unless specifically instructed by a healthcare professional.

Serious risks include severe dehydration, acute kidney injury, hyperkalemia, and angioedema. Patients should be monitored for sudden drops in blood pressure, signs of electrolyte imbalance, and any swelling of the face, lips, or throat, which require immediate medical attention.

Monexe is contraindicated in patients with known hypersensitivity to valsartan, hydrochlorothiazide, or any component of the formulation. It should also be avoided in pregnancy, severe renal impairment, and in individuals with hyperkalemia or significant electrolyte disturbances.